NASDAQ · IDYA
Healthcare · Biotechnology
$37.36
Up+$0.70 (+1.87%)
Updated Oct 5, 2026, 11:06 PM
SID Score
5.5/10
Composite research score
Smart Money
58/100
Neutral
Price performance · IDYA
1M range · 19 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
IDYA closed at $37.36 after 19 trading sessions, down 3.81% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $38.52 | $38.54 | $37.00 | $37.36 | 579.05K |
| Oct 1, 2026 | $38.34 | $39.32 | $37.62 | $37.81 | 712.27K |
| Sep 30, 2026 | $38.11 | $39.39 | $37.76 | $38.42 | 1.02M |
| Sep 29, 2026 | $38.14 | $38.425 | $37.20 | $37.86 | 815.45K |
| Sep 28, 2026 | $36.26 | $38.73 | $36.10 | $38.22 | 1.05M |
| Sep 25, 2026 | $36.74 | $36.985 | $36.16 | $36.69 | 487.29K |
| Sep 24, 2026 | $37.46 | $37.78 | $35.59 | $36.74 | 1.27M |
| Sep 23, 2026 | $39.74 | $39.88 | $37.00 | $37.46 | 2.24M |
| Sep 22, 2026 | $39.11 | $40.00 | $38.93 | $39.71 | 745.79K |
| Sep 21, 2026 | $38.705 | $39.00 | $37.985 | $38.86 | 571.1K |
| Sep 18, 2026 | $38.88 | $39.245 | $38.15 | $38.41 | 2.49M |
| Sep 17, 2026 | $38.61 | $39.47 | $38.53 | $38.61 | 757.77K |
| Sep 16, 2026 | $37.71 | $38.46 | $37.24 | $37.73 | 639.91K |
| Sep 15, 2026 | $37.88 | $38.24 | $37.125 | $37.66 | 654.23K |
| Sep 14, 2026 | $38.50 | $39.33 | $37.74 | $38.03 | 524.74K |
| Sep 11, 2026 | $37.74 | $38.27 | $37.24 | $37.59 | 429.25K |
| Sep 10, 2026 | $37.85 | $38.405 | $37.37 | $37.45 | 547.79K |
| Sep 9, 2026 | $39.19 | $39.19 | $38.21 | $38.35 | 488.55K |
| Sep 8, 2026 | $38.90 | $39.4699 | $38.59 | $38.84 | 805.96K |
The latest Smart Investors Daily articles mentioning IDYA.
Company
Market Activity
Research & News
IDYA research
Company profile and research snapshot.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Guggenheim | Buy | — |
| Sep 1, 2026 | Citizens | Market Outperform | — |
| Aug 5, 2026 | Wedbush | Outperform | — |
| Aug 5, 2026 | Truist Securities | Buy | — |
| Jul 7, 2026 | RBC Capital | Outperform | — |
No generated briefing is available yet.
Yahoo · Sep 28, 2026
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the promotion of Dr. Michael White, from Chief Scientific Officer to President, Research and Development, effective September 28, 2026.
Yahoo · Sep 25, 2026
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on September 24, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 94,000 shares of the Company's common stock to three newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award
SeekingAlpha · Sep 14, 2026
IDEAYA Biosciences, Inc. (IDYA) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 7:00 AM EDTCompany ParticipantsYujiro Hata -...
SeekingAlpha · Sep 10, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IDYA.
